Provided by Tiger Fintech (Singapore) Pte. Ltd.

Jasper Therapeutics

5.94
-0.0700-1.16%
Post-market: 5.85-0.0900-1.52%19:22 EDT
Volume:223.57K
Turnover:1.34M
Market Cap:89.23M
PE:-1.13
High:6.10
Open:6.05
Low:5.86
Close:6.01
Loading ...

Jasper Therapeutics Inc : Btig Cuts Target Price to $64 From $90

THOMSON REUTERS
·
09 Jan

Jasper Therapeutics Inc : RBC Cuts Target Price to $48 From $68

THOMSON REUTERS
·
09 Jan

Promising Efficacy and Safety of Jasper Therapeutics’ Briquilimab Boosts Buy Rating

TIPRANKS
·
09 Jan

Jasper Therapeutics price target lowered to $64 from $90 at BTIG

TIPRANKS
·
09 Jan

Jasper BEACON data ‘net positive,’ says BMO Capital

TIPRANKS
·
09 Jan

Crude Oil Down 1%; US Weekly Jobless Claims Decline

Benzinga
·
09 Jan

BUZZ-Jasper Therapeutics falls about 50% after early-stage data for skin disease drug

Reuters
·
08 Jan

Jasper Therapeutics Shares Fall 50% Premarket After Early-Stage Data From Co's Skin Disease Drug

THOMSON REUTERS
·
08 Jan

Jasper Therapeutics Says Preliminary Study Data for Urticaria Treatment Show Reduced Disease Activity

MT Newswires Live
·
08 Jan

BRIEF-Jasper Therapeutics Reports Positive Data From Beacon Study Of Briquilimab In Chronic Spontaneous Urticaria

Reuters
·
08 Jan

Jasper Therapeutics Inc - Data Supports Commencement of Csu Registrational Program Expected to Commence Second Half of 2025

THOMSON REUTERS
·
08 Jan

Jasper Therapeutics Inc - 100% Complete Responses in 240Mg Cohort at 8 Weeks

THOMSON REUTERS
·
08 Jan

Jasper Therapeutics Reports Positive Data From Beacon Study of Briquilimab in Chronic Spontaneous Urticaria

THOMSON REUTERS
·
08 Jan

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

GlobeNewswire
·
08 Jan

Jasper Therapeutics: Promising Growth Potential in the Urticaria Market with Briquilimab’s Emerging Efficacy Profile

TIPRANKS
·
07 Jan

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

GlobeNewswire
·
06 Jan

Jasper Therapeutics Positioned for Success in Urticaria Market with Upcoming Briquilimab Data

TIPRANKS
·
06 Jan

Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Deliver On Growth Plans?

Simply Wall St.
·
04 Jan

Analysts Are Bullish on These Healthcare Stocks: Jasper Therapeutics (JSPR), Celldex (CLDX)

TIPRANKS
·
02 Jan

Jasper Therapeutics Price Target Maintained With a $68.00/Share by RBC Capital

Dow Jones
·
23 Dec 2024